Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits candida albicans and staphylococcus aureus biofilm formation in vivo

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7606-7610

  De Cremer, Kaat ^a,b   Delattin, Nicolas ^a   De Brucker, Katrijn ^a   Peeters, Annelies ^a   Kucharíková, Soña ^a   Gerits, Evelien ^a   Verstraeten, A Natalie ^a   Michiels, Jan ^a   Van Dijck, Patrick ^a   Cammue, Bruno P A ^a,b   Thevissen, Karin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; TAMOXIFEN; TOREMIFENE; ANTIINFECTIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOFILM; BONE DENSITY; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA KRUSEI; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; EDEMA; FEMALE; HOT FLUSH; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; RAT; STAPHYLOCOCCUS AUREUS; VAGINA BLEEDING; VAGINA DISCHARGE; VOMITING; ANIMAL; CANDIDA; CANDIDIASIS, CUTANEOUS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INDWELLING CATHETER; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN; SPRAGUE DAWLEY RAT; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS, CUTANEOUS; CATHETERS, INDWELLING; FEMALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TOREMIFENE;

EID: 84912122913     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03869-14     Document Type: Article

References (51)

1. Costerton JW, Montanaro L, Arciola CR. 2005. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs 28:1062-1068.
2. Ramage G, Robertson SN, Williams C. 2014. Strength in numbers: antifungal strategies against fungal biofilms. Int. J. Antimicrob. Agents 43:114-120. http://dx.doi.org/10.1016/j.ijantimicag.2013.10.023.
3. Walz JM, Memtsoudis SG, Heard SO. 2010. Prevention of central venous catheter bloodstream infections. J. Intensive Care Med. 25:131-138. http: //dx.doi.org/10.1177/0885066609358952.
4. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl 7):S19-S37. http://dx.doi.org /10.1111/1469-0691.12039.
5. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi .org/10.1086/596757.
6. Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, Rizzi M, Suter F, Utili R, Viscoli C, Venditti M. 2009. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 88: 160-168. http://dx.doi.org/10 .1097/MD.0b013e3181a693f8.
7. Dutronc H, Dauchy FA, Cazanave C, Rougie C, Lafarie-Castet S, Couprie B, Fabre T, Dupon M. 2010. Candida prosthetic infections: case series and literature review. Scand. J. Infect. Dis. 42:890-895. http://dx .doi.org/10.3109/00365548.2010.498023.
8. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189. http://dx.doi.org/10.1086/380796.
9. Otto M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228. http://dx.doi.org/10.1007/978-3-540-75418-3-10.
10. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx .doi.org/10.1126/science.284.5418.1318.
11. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18 -55. http://dx.doi.org/10 .1093/cid/ciq146.
12. Deresinski S. 2009. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 49:1072-1079. http://dx.doi.org/10.1086 /605572.
13. Janknegt R. 1997. The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Pharm. World Sci. 19:133-141. http://dx.doi.org /10.1023/A:1008609718457.
14. Schito GC. 2006. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl 1):S3-S8. http://dx.doi.org/10.1111/j.1469-0691.2006.01343.x.
15. Delattin N, De Brucker K, Vandamme K, Meert E, Marchand A, Chaltin P, Cammue BP, Thevissen K. 2014. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J. Antimicrob. Chemother. 69:1035-1044. http://dx.doi .org/10.1093/jac/dkt449.
16. Taras TL, Wurz GT, Linares GR, DeGregorio MW. 2000. Clinical pharmacokinetics of toremifene. Clin. Pharmacokinet. 39:327-334. http: //dx.doi.org/10.2165/00003088-200039050-00002.
17. Butts A, Koselny K, Chabrier-Rosello Y, Semighini CP, Brown JC, Wang X, Annadurai S, Didone L, Tabroff J, Childers WE, Jr, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, Krysan DJ. 2014. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 5(1):e00765-13. http://dx.doi.org/10.1128/mBio.00765-13.
18. Wiseman H, Cannon M, Arnstein HR, Halliwell B. 1993. Enhancement by tamoxifen of the membrane antioxidant action of the yeast membrane sterol ergosterol: relevance to the antiyeast and anticancer action of tamoxifen. Biochim. Biophys. Acta 1181: 201-206. http://dx .doi.org/10.1016/0925-4439(93)90021-R.
19. Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho CH, Wang J, Ketela T, Brenner C, Brill JA, Fernandez GE, Lorenz TC, Payne GS, Ishihara S, Ohya Y, Andrews B, Hughes TR, Frey BJ, Graham TR, Andersen RJ, Boone C. 2006. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126:611-625. http://dx.doi.org/10.1016/j.cell.2006.06 .040.
20. Dolan K, Montgomery S, Buchheit B, Didone L, Wellington M, Krysan DJ. 2009. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53: 3337-3346. http://dx.doi.org/10.1128/AAC.01564-08.
21. Ricicova M, Kucharikova S, Tournu H, Hendrix J, Bujdakova H, Van Eldere J, Lagrou K, Van Dijck P. 2010. Candida albicans biofilm formation in a new in vivo rat model. Microbiology 156:909-919. http://dx.doi .org/10.1099/mic.0.033530-0.
22. Delattin N, De Brucker K, Craik DJ, Cheneval O, Frohlich M, Veber M, Girandon L, Davis TR, Weeks AE, Kumamoto CA, Cos P, Coenye T, De Coninck B, Cammue BP, Thevissen K. 2014. Plant-derived decapeptide OSIP108 interferes with Candida albicans biofilm formation without affecting cell viability. Antimicrob. Agents Chemother. 58:2647-2656. http: //dx.doi.org/10.1128/AAC.01274-13.
23. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BP, Thevissen K. 2011. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob. Agents Chemother. 55: 4033-4037. http://dx.doi.org/10.1128/AAC.00280-11.
24. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372. http: //dx.doi.org/10.1146/annurev.micro.112408.134306.
25. Kint CI, Verstraeten N, Fauvart M, Michiels J. 2012. New-found fundamentals of bacterial persistence. Trends Microbiol. 20:577-585. http: //dx.doi.org/10.1016/j.tim.2012.08.009.
26. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeast, approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Harrison JJ, Stremick CA, Turner RJ, Allan ND, Olson ME, Ceri H. 2010. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat. Protoc. 5:1236-1254. http://dx.doi.org/10.1038/nprot.2010.71.
28. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehar J, Hensley LE, White JM, Olinger GG. 2013. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5:190ra79. http://dx.doi.org/10.1126/scitranslmed.3005471.
29. Kangas L, Paul R, Kellokumpu-Lehtinen P, Harju-Jeanty R, Tuominen J. 1989. Rats with mammary cancer treated with toremifene and interferon: morphometry and needle aspiration biopsy for determination of ATP and 14C-fluorodeoxyglucose content. Res. Exp. Med. (Berl.) 189: 113-119. http://dx.doi.org/10.1007/BF01851261.
30. Huovinen R, Kellokumpu-Lehtinen PL, Collan Y. 1994. Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma. Int. J. Exp. Pathol. 75:257-263.
31. Huovinen RL, Alanen KA, Collan YU. 1995. Cell proliferation in dimethylbenz (A)anthracene(DMBA)-induced rat mammary carcinoma treated with antiestrogen toremifene. Acta Oncol. 34:479-485. http://dx .doi.org/10.3109/02841869509094011.
32. Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R. 1986. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother. Pharmacol. 17:109-113. http://dx.doi.org/10.1007/BF00306737.
33. di Salle E, Zaccheo T, Ornati G. 1990. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J. Steroid Biochem. 36: 203-206. http://dx.doi.org/10.1016/0022 -4731(90)90005-D.
34. Williams GM, Ross PM, Jeffrey AM, Karlsson S. 1998. Genotoxicity studies with the antiestrogen toremifene. Drug Chem. Toxicol. 21:449-476. http://dx.doi.org/10.3109/01480549809002216.
35. Kanaya Y, Doihara H, Shiroma K, Ogasawara Y, Date H. 2008. Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice. Surg. Today 38:911-920. http://dx.doi.org/10.1007/s00595-007-3730-2.
36. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. 2010. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob. Agents Chemother. 54: 4474-4475. http://dx.doi.org/10 .1128/AAC.00697-10.
37. Bink A, Kucharikova S, Neirinck B, Vleugels J, Van Dijck P, Cammue BP, Thevissen K. 2012. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J. Infect. Dis. 206:1790-1797. http://dx.doi.org/10.1093 /infdis/jis594.
38. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG. 2004. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob. Agents Chemother. 48:1272-1280. http://dx.doi.org/10.1128/AAC.48.4.1272-1280 .2004.
39. Morello KC, Wurz GT, DeGregorio MW. 2003. Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42:361-372. http://dx.doi.org/10.2165/00003088-200342040-00004.
40. Gershanovich M, Hayes DF, Ellmen J, Vuorinen J. 1997. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) 11(5 Suppl 4):29-36.
41. Zejnalov RS, Musaev IN, Giyasbejli SR, Dadasheva NR, Gasanzade DA, Yusifov AI, Akhadova NA. 2006. Comparative analysis of the efficacy of toremifeine, tamoxifen and letrozole in treatment of patients with disseminated breast cancer. Onkologiya 8:1-4. (In Russian.)
42. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. 1997. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res. Treat. 45:251-262. http://dx.doi.org/10 .1023/A:1005891506092.
43. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I. 1995. Randomized comparison of tamoxifen and two separate doses of toremifene in post-menopausal patients with metastatic breast cancer. J. Clin. Oncol. 13: 2556-2566.
44. Mustonen MV, Pyrhonen S, Kellokumpu-Lehtinen PL. 2014. Toremifene in the treatment of breast cancer. World J. Clin. Oncol. 5:393-405.
45. Vogel CL, Johnston MA, Capers C, Braccia D. 2014. Toremifene for breast cancer: a review of 20 years of data. Clin. Breast Cancer 14:1-9. http://dx.doi.org/10.1016/j.clbc.2013.10.014.
46. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
47. Kaur R, Ma B, Cormack BP. 2007. A family of glycosylphosphatidyli-nositol-linked aspartyl proteases is required for virulence of Candida glabrata. Proc. Natl. Acad. Sci. U. S. A. 104:7628-7633. http://dx.doi.org /10.1073/pnas.0611195104.
48. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 141(Pt 7):1507-1521. http://dx.doi.org/10 .1099/13500872-141-7-1507.
49. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, Miyata S, Diggins LT, He J, Saucier M, Deziel E, Friedman L, Li L, Grills G, Montgomery K, Kucherlapati R, Rahme LG, Ausubel FM. 2006. Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol. 7:R90. http://dx.doi.org/10.1186/gb-2006-7-10 -r90.
50. Costerton JW, Marrie TJ, Cheng KJ. 1985. Phenomena of bacterial adhesion, p 3-43. In Savage DC, Fletcher M (ed), Bacterial adhesion. Springer, New York, NY.
51. O'Neill AJ. 2010. Staphylococcus aureus SH1000 and 8325-4: comparative genome sequences of key laboratory strains in staphylococcal research. Lett. Appl. Microbiol. 51:358-361. http://dx.doi.org/10.1111/j.1472-765X .2010.02885.x.